Standard Review for Gilead's Oncology Candidate Yahoo News The patients were refractory to both Roche's (OTC:RHHBY) Rituxan (rituximab) and to chemotherapy inclusive alkylating-agent. A decision from the FDA is expected by Sep 11, 2014. Apart from iNHL, idelalisib is also being evaluated in other oncology ... |
